Rein Therapeutics
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Rein Therapeutics
Rein Therapeutics, Inc., incorporated under Delaware law on August 6, 2001, commenced operations in 2006. The company is a clinical-stage biopharmaceutical firm focused on developing and commercializing a novel class of therapeutic agents known as stapled peptides. Its lead candidate, ALRN-6924, targets the tumor suppressor gene p53 and is being investigated for the treatment of a broad range of cancers. Currently undergoing multiple clinical trials, ALRN-6924 works by reactivating p53-mediated tumor suppression through selectively targeting two principal p53 inhibitory proteins, MDMX and MDM2. Ongoing clinical studies for ALRN-6924 include a Phase 1 trial in patients with advanced solid tumors or lymphomas; a Phase 2a trial for peripheral T-cell lymphoma (PTCL); a Phase 1 trial for acute-phase PTCL; and Phase 1b trials evaluating ALRN-6924 both as monotherapy and in combination with cytarabine (Ara-C) for acute myeloid leukemia (AML) and advanced myelodysplastic syndromes (MDS). For more information, visit the company’s website at http://www.aileronrx.com. The company is headquartered at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
How to Buy Rein Therapeutics (RNTX)
Sign In
1-Minute Account Opening
Complete your account application and verification in just 1 minute. The process is fully self-service and available on both RockFlow App and Web.
Deposit funds
Once your account has been verified, you can deposit funds into your account using your preferred payment method.
Buy RNTX
Search for RNTX via RockFlow App or Web, enter the amount you want to invest, and tap Confirm to execute the trade.
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.